Claritev: Cash Flow Improves, But The Debt And Margin Story Keeps This A Hold

Claritev (NYSE: CTEV) reported second-quarter 2026 results today that contain three good things and one bad one that overshadows all of them. Revenue grew 6.6% year-over-year to $257.5 million, marking the fifth consecutive quarter of growth. Operating cash flow jumped 51% to $92.7 million and free cash flow rose 49% to $54.6 million. Management raised every element of its full-year guidance.

The bad one is margin. Adjusted EBITDA of $155.8 million increased 1.1% while revenue grew 6.6%, which means the cost of producing those sales is rising faster than the sales themselves. The adjusted EBITDA margin contracted 330 basis points to 60.5%, down from 63.8% a year ago. Costs of services rose 11.3% and general and administrative expenses rose 8.4%. Revenue growth is real. The question is whether the business is growing into profitability or just growing more expensive.

On top of that, Claritev carries $4.59 billion in long-term debt. Interest expense for the quarter was $100.3 million — more than four times the $23.4 million in operating income. That interest burden alone explains the $59.2 million net loss and the $287.8 million shareholders' deficit on the balance sheet. The company also drew an additional $50 million on its revolving credit facility, bringing revolver borrowings to $70 million from $20 million at year-end.

Claritev trades at a $458 million market cap, but its enterprise value is $5.15 billion. The market cap looks cheap because the stock has fallen from a 52-week high of $74 to its current $27, a decline of more than 53% over the trailing year. But the enterprise value is the number that matters when a company carries $4.6 billion in net debt and only $14.4 million in unrestricted cash. At an EV/EBITDA of 14.2x on a business that just saw its margin compress by over three percentage points, the stock is not a valuation mistake. It is priced where the debt and margin trajectory warrant.

What the quarter actually showed

Revenue growth of 6.6% is solid for a company that spent its first two fiscal years of 2026 rebuilding after the MultiPlan rebrand and debt restructuring. The growth is diversified across Claritev's four segments: Claims Intelligence (out-of-network claim resolution and No Surprises Act services), Payment & Revenue Integrity (pre-payment and post-payment error correction), Data & Analytics (benefit plan design optimization), and Provider Solutions (price transparency for hospitals).

Management reported over $70 million in bookings during the first half of 2026, against a full-year target of $100 million — a 50% increase over 2025. Several seven-figure transactions closed in the third-party administrator market, which is a new vertical for the company. The bookings pipeline gives the revenue growth a visible runway, though the timing of revenue recognition from bookings was not disclosed.

The cash flow improvement deserves attention. Operating cash flow of $92.7 million compared to $61.2 million a year ago, with a favorable $5.3 million swing from accounts receivable collection (versus using $30.1 million in receivables a year ago). Free cash flow of $54.6 million came after capital expenditures of $38.1 million, up 55% year-over-year as the company invests in its Oracle Cloud infrastructure and AI-enabled tools. The raised FCF guidance of $5 million to $15 million for the full year suggests management expects capex intensity to remain elevated while cash conversion holds up.

Why the margin contraction is the story

The 330 basis-point drop in adjusted EBITDA margin is not a one-off accounting blip. It reflects a structural tension: Claritev is growing its cost base faster than its revenue base while the revenue growth rate itself is only in the low-to-mid single digits. On a $1 billion annual revenue run rate, a 60.5% adjusted EBITDA margin generates roughly $605 million in annual adjusted EBITDA. After $400 million+ in annual interest expense (quarterly interest was $100.3 million), the remaining cash to service principal, fund growth, and return capital to shareholders is narrow.

That is not to say the margin trend is irreversible. The company has invested over $500 million in R&D during the past five years and now has a Chief AI Officer driving AI-enabled tools across its workflows. The PHCS Novera primary network product launches September 1st, and the Claims Optimizer tool has expanded internationally. If those investments drive operating leverage in the second half of 2026 or into 2027, the margin could stabilize and recover.

But operating leverage requires either revenue growth to accelerate above current levels or costs to stop growing faster than sales. Neither condition has happened yet. Revenue grew 6.6% in Q2 after 5.8% in Q1. Costs of services grew 11.3%. That is a pattern, not a one-quarter anomaly.

The capital structure

The balance sheet is the dominant risk in this stock. $4.59 billion in long-term debt, $287.8 million in negative shareholders' equity, and $14.4 million in unrestricted cash. The company completed a debt restructuring in 2024, but the leverage ratio remains extreme. For context, the debt-to-equity ratio reported by the market data service reads at negative multiples because equity itself is deeply underwater. That is a technical marker of what the capital structure looks like: all debt, no equity cushion.

Nine insider purchase entries between late February and early June totaled approximately $1.49 million, with CEO Travis Dalton buying shares worth over $340,000 on May 18. Insider buying at the current price range signals confidence in the turnaround thesis from management. That matters — it is real skin in the game — but it does not change the math on $100 million in quarterly interest expense. Management may believe the operating cash flow trajectory and growth investments will eventually de-lever the balance sheet. The FCF guidance of $5 million to $15 million for the year is a start, but at current debt levels, it is a very small start.

Raised guidance: modest, not transformative

Management raised its full-year 2026 guidance across the board. Revenue moved from $985 million to $1.00 billion on the low end and from $1.00 billion to $1.02 billion on the high end. Adjusted EBITDA increased $5 million at both ends to $610 million to $620 million. Free cash flow guidance rose from $0 to $10 million to $5 million to $15 million.

The raises are directionally positive but not large enough to signal that the margin problem has been solved. Revenue guidance implies roughly $595 million in the second half, or about $297 million per quarter. That would represent continued growth over Q2's $257.5 million, which is encouraging. But the adjusted EBITDA guidance of $610 million to $620 million on $1 billion+ in revenue implies a blended annual margin of roughly 60%, still well below the 63.8% the company posted a year ago.

Valuation context

Claritev trades at 0.47x trailing sales, which looks cheap on the price-to-sales metric alone. But that metric ignores the $4.6 billion in net debt sitting between the market cap and the business. On an EV/EBITDA basis at 14.2x, the stock is not cheap for a company with 5.5% revenue growth and a contracting margin. Healthcare data infrastructure names that generate positive free cash flow and grow at similar rates trade at lower enterprise-value multiples because they do not carry this level of leverage.

The stock is up 13.8% over the past five trading sessions, suggesting some relief buying after the Q2 release. But the 52-week high is $74, the current price is $27, and the stock is down 37% year-to-date. There is still a long way to go before this multiple reflects a healthy capital structure.

Risks and what would change the call

The primary risk is margin deterioration. If adjusted EBITDA margin continues to compress toward the low 60% range or below, the gap between operating cash flow and interest expense narrows further. That creates refinancing risk when debt maturities come due.

The secondary risk is booking conversion. Management targeted $100 million in full-year bookings, up 50% from 2025, with $70 million already secured in the first half. But bookings do not equal revenue. The timing and rate at which those bookings convert into recognized revenue is the metric that will tell whether the growth story has real traction or is front-loaded with promises.

The tertiary risk is competitive pressure. Claritev operates in a space where Optum, Zelis, Magellan Health, and payer-owned solutions compete for the same claims integrity and cost management contracts. Margin erosion can also reflect pricing pressure from larger competitors with deeper balance sheets.

The investor takeaway

Claritev is a business in genuine transition. Revenue growth is positive and accelerating slightly, bookings are expanding into new verticals, cash flow generation improved sharply, and guidance was raised across every metric. Nine insider purchases add credibility to the management thesis.

But the margin contraction, the $4.59 billion debt load, the $100 million quarterly interest expense, and the negative shareholders' equity tell a different story about where this company stands today. The enterprise value multiple reflects those realities. The stock is cheap on price-to-sales only because the market cap ignores the debt. On an enterprise-value basis, it is priced where the risk warrants.

Rating: Hold. The operating business is moving in the right direction. The capital structure is still too dangerous to buy into aggressively. Watch for three things: whether adjusted EBITDA margin stabilizes or recovers in Q3, whether the second-half booking conversion supports the raised revenue guidance, and whether free cash flow generation is large enough to begin meaningfully reducing the debt load. Until one of those conditions changes, the risk/reward does not support a buy.

The next catalyst is the Q3 earnings release, expected in early November, which will show whether the margin contraction is a Q2 aberration or a trend. If the margin holds at 60% or better and FCF for the first nine months is on track for the upper end of the guidance range, the case for an upgrade becomes real. If the margin dips further and debt increases, the case for stepping aside does too.